President, R&D & CMO · Maze Therapeutics, Inc. · Common Stock
Side
M
Value
$4,293
Shares
412
Price
$10.42
Executed
Jan 5, 2026
Disclosed
Jan 6, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Jan 5 executedJan 6, 2026 disclosed
MAZE · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Option exercise — administrative, little informational value
Relative size+1 / 25
$4K reported value · new position
Filing timing0 / 15
Disclosed 1 business day after execution (deadline: 2)
Historical behavior+4 / 15
3 prior trades recorded in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
Pre-arranged plan-10
Executed under a Rule 10b5-1 trading plan
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Bernstein Harold filed this Form 4 reporting a option exercise of MAZE on Jan 5, 2026. It became public on Jan 6, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
President, R&D & CMO
Bernstein Haroldcik:0002050172
Issuer
Maze Therapeutics, Inc.cik:0001842295
Revision history · 0
No field has changed since this record was first ingested.
